Genetic association of acyl-coenzyme A: Cholesterol acyltransferase with cerebrospinal fluid cholesterol levels, brain amyloid load, and risk for Alzheimer's disease

Molecular Psychiatry

Volumn 8, Issue 6, 2003, Pages 635-638

  Wollmer, M A ^a   Streffer, J R ^a   Tsolaki, M ^b   Grimaldi, L M E ^c,d   Lutjohann D ^e   Thal, D ^e   Von Bergmann, K ^e   Nitsch, R M ^a   Hock, C ^a   Papassotiropoulos, A ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d AUSL 2   (Italy)

^e UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

ACAT1; Case control study; Dementia; Polymorphism; SNP; SOAT1

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; ENZYMOLOGY; ETHNOLOGY; FEMALE; GENE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETICS; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METABOLISM; NEUROPATHOLOGY; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SOAT1 GENE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BRAIN; CHOLESTEROL; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS; STEROL O-ACYLTRANSFERASE;

EID: 10744223627     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4001296     Document Type: Article

References (20)

1. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81: 741-766.
2. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 1998; 95: 6460-6464.
3. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P et al. Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 2001; 98: 5856-5861.
4. Rudel LL, Lee RG, Cockman TL. Acyl coenzyme A: cholesterol acyltransferase types 1 and 2: structure and function in atherosclerosis. Curr Opin Lipidol 2001; 12: 121-127.
5. Puglielli L, Konopka G, Pack-Chung E, Ingano LA, Berezovska O, Hyman BT et al. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat Cell Biol 2001; 3: 905-912.
6. Kehoe P, Wavrant-De Vrieze F, Crook R, Wu WS, Holmans P, Fenton I et al. A full genome scan for late onset alzheimer's disease. Hum Mol Genet 1999; 8: 237-245.
7. Myers A, Wavrant De-Vrieze F, Holmans P, Hamshere M, Crook R, Compton D et al. Full genome screen for Alzheimer disease: Stage II analysis. Am J Med Genet 2002; 114: 235-244.
8. Sullivan PF, Eaves LJ, Kendler KS, Neale MC. Genetic case-control association studies in neuropsychiatry. Arch Gen Psychiatry 2001; 58: 1015-1024.
9. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
10. Thal DR, Rub U, Schultz C, Sassin I, Ghebremedhin E, Del Tredici K et al. Sequence of Abeta-protein deposition in the human medial temporal lobe. J Neuropathol Exp Neurol 2000; 59: 733-748.
11. Thal DR, Rüb U, Orantes M, Braak H. Phases of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology 2002; 58: 1791-1800.
12. Braak H, Braak E Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-259.
13. Dzeletovic S, Breuer O, Lund E, Diczfalusy U. Determination of cholesterol oxidation products in human plasma by isotope dilution-mass spectrometry. Anal Biochem 1995; 225: 73-80.
14. Demeester N, Castro G, Desrumaux C, De Geitere C, Fruchart JC, Santens P et al. Characterization and functional studies of lipoproteins, lipid transfer proteins, and lecithin: cholesterol acyltransferase in CSF of normal individuals and patients with Alzheimer's disease. J Lipid Res 2000; 41: 963-974.
15. Montine TJ, Montine KS, Swift LL. Central nervous system lipoproteins in Alzheimer's disease. Am J Pathol 1997; 151: 1571-1575.
16. Mulder M, Ravid R, Swaab DF, de Kloet ER, Haasdijk ED, Julk J et al. Reduced levels of cholesterol, phospholipids, and fatty acids in cerebrospinal fluid of Alzheimer disease patients are not related to apolipoprotein E4. Alzheimer Dis Assoc Disord 1998; 12: 198-203.
17. Accad M, Smith SJ, Newland DL, Sanan DA, King Jr LE, Linton MF et al. Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA: cholesterol acyltransferase 1. J Clin Invest 2000; 105: 711-719.
18. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990; 31: 545-548.
19. Kokoris M, Dix K, Moynihan K, Mathis J, Erwin B, Grass P et al. High-throughput SNP genotyping with the Masscode system. Mol Diagn 2000; 5: 329-340.
20. Terwilliger JD, Ott J. Linkage disequilibrium between alleles at marker loci. In: Terwilliger JD and Ott J (eds). Handbook of Human Genetic Linkage. The Johns Hopkins University Press: Baltimore, 1994, p. 189-198.